专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO02077275A3 DIAGNOSTIC METHOD FOR DETERMINING ABNORMALITY OF CLONED EMBRYOS 审中-公开
标题翻译：用于确定克隆胚胎异常的诊断方法
公开(公告)号：WO02077275A3
公开(公告)日：2003-08-07
申请号：PCT/GB0201398
申请日：2002-03-22
申请人： BABRAHAM INST , DEAN WENDY LEE , REIK WOLF
发明人： DEAN WENDY LEE , REIK WOLF
IPC分类号： C12N15/873 , C12Q1/68 , A01K67/027 , A61K31/70 , A61K31/7068 , C07K16/18 , C12N15/00 , G01N33/50
CPC分类号： C12N15/873
摘要： The present invention relates to a method for determining abnormal development of cloned embryos. The method provides for the detection and/or measurement of aberrant epigenetic reprogramming in cloned mammalian embryos. Aberrant reprogramming may lead to abnormality in cloned embryos. According to a first aspect of the invention there is provided a method for detecting and/or measuring aberrant epigenetic reprogramming in a cloned mammalian embryo, which includes the step of determining the methylation state of said embryo. According to a second aspect of the invention there is provided a method of diagnosis of aberrant epigenetic reprogramming in a cloned mammalian embryo, which includes the step of determining the methylation state of said embryo. Furthermore, the invention provides a method of diagnosis of the propensity of a cloned mammalian embryo for abnormal development, which method includes the step of determining the methylation state of said embryo.
摘要翻译：本发明涉及一种确定克隆胚胎异常发育的方法。该方法提供克隆哺乳动物胚胎中异常表观遗传重编程的检测和/或测量。异常重编程可能导致克隆胚胎异常。根据本发明的第一方面，提供了用于检测和/或测量克隆的哺乳动物胚胎中异常表观遗传重编程的方法，其包括测定所述胚胎的甲基化状态的步骤。根据本发明的第二方面，提供了一种在克隆的哺乳动物胚胎中诊断异常表观遗传重编程的方法，其包括确定所述胚胎的甲基化状态的步骤。此外，本发明提供了诊断克隆的哺乳动物胚胎异常发育倾向的方法，该方法包括确定所述胚胎的甲基化状态的步骤。

2. 发明申请

WO2002077275A2 DIAGNOSTIC METHOD FOR DETERMINING ABNORMALITY OF CLONED EMBRYOS 审中-公开
标题翻译：用于确定克隆胚胎异常的诊断方法
公开(公告)号：WO2002077275A2
公开(公告)日：2002-10-03
申请号：PCT/GB2002/001398
申请日：2002-03-22
申请人： BABRAHAM INSTITUTE , DEAN, Wendy, Lee , REIK, Wolf
发明人： DEAN, Wendy, Lee , REIK, Wolf
IPC分类号： C12Q1/68
CPC分类号： C12N15/873
摘要： The present invention relates to a method for determining abnormal development of cloned embryos. The method provides for the detection and/or measurement of aberrant epigenetic reprogramming in cloned mammalian embryos. Aberrant reprogramming may lead to abnormality in cloned embryos. According to a first aspect of the invention there is provided a method for detecting and/or measuring aberrant epigenetic reprogramming in a cloned mammalian embryo, which includes the step of determining the methylation state of said embryo. According to a second aspect of the invention there is provided a method of diagnosis of aberrant epigenetic reprogramming in a cloned mammalian embryo, which includes the step of determining the methylation state of said embryo. Furthermore, the invention provides a method of diagnosis of the propensity of a cloned mammalian embryo for abnormal development, which method includes the step of determining the methylation state of said embryo.
摘要翻译：本发明涉及一种确定克隆胚胎异常发育的方法。该方法提供克隆哺乳动物胚胎中异常表观遗传重编程的检测和/或测量。异常重编程可能导致克隆胚胎异常。根据本发明的第一方面，提供了用于检测和/或测量克隆的哺乳动物胚胎中异常表观遗传重编程的方法，其包括测定所述胚胎的甲基化状态的步骤。根据本发明的第二方面，提供了一种在克隆的哺乳动物胚胎中诊断异常表观遗传重编程的方法，其包括确定所述胚胎的甲基化状态的步骤。此外，本发明提供了诊断克隆的哺乳动物胚胎异常发育倾向的方法，该方法包括确定所述胚胎的甲基化状态的步骤。

3. 发明授权

US08637537B2 Serine/threonine kinase inhibitors 失效
标题翻译：丝氨酸/苏氨酸激酶抑制剂
公开(公告)号：US08637537B2
公开(公告)日：2014-01-28
申请号：US13593776
申请日：2012-08-24
申请人： Ignacio Aliagas-Martin , James Crawford , Wendy Lee , Simon Mathieu , Joachim Rudolph
发明人： Ignacio Aliagas-Martin , James Crawford , Wendy Lee , Simon Mathieu , Joachim Rudolph
IPC分类号： A01N43/54 , A61K31/505
CPC分类号： C07D403/14 , A61K31/506 , A61K45/06
摘要： Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
摘要翻译：具有式I的化合物，其中A，Z，R 1a，R 1b，R 2，R 3，R 4，R 5，R 6，R 7，R 9，R 10，R a，R b和n如本文所定义是PAK1的抑制剂。还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。

4. 发明授权

US08580798B2 Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders 失效
标题翻译：可用于治疗癌症和其他疾病的取代嘧啶衍生物
公开(公告)号：US08580798B2
公开(公告)日：2013-11-12
申请号：US12158524
申请日：2006-12-20
申请人： Roger Smith , Jacques Dumas , Gan Wang , Wendy Lee , Karl Miranda
发明人： Roger Smith , Jacques Dumas , Gan Wang , Wendy Lee , Karl Miranda
IPC分类号： C07D401/12 , A61K31/506
CPC分类号： C07D401/12
摘要： Substituted pyrimidine derivatives of formula (I), salts, metabolites, prodrugs and diastereoisomeric forms (both isolated stereoisomers and mixtures of stereoisomers) thereof (wherein A=pyrimidine) pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with other active ingredients, e.g., cytotoxic therapies.
摘要翻译：式（I）的取代的嘧啶衍生物，其盐，代谢物，前药和非对映异构体形式（分离的立体异构体和立体异构体的混合物）（其中A =嘧啶）含有这些化合物的药物组合物以及这些化合物或组合物用于治疗增殖和血管生成障碍，作为唯一的药剂或与其它活性成分组合，例如细胞毒性疗法。

5. 发明申请

US20130039906A1 PYRAZOLO[3,4-c]PYRIDINE COMPOUNDS AND METHODS OF USE 有权
标题翻译：吡咯并[3,4-c]吡啶化合物及其使用方法
公开(公告)号：US20130039906A1
公开(公告)日：2013-02-14
申请号：US13571595
申请日：2012-08-10
申请人： Steven Do , Huiyong Hu , Aleksandr Kolesnikov , Wendy Lee , Vickie H. Tsui , Xiaojing Wang , Zhaoyang Wen
发明人： Steven Do , Huiyong Hu , Aleksandr Kolesnikov , Wendy Lee , Vickie H. Tsui , Xiaojing Wang , Zhaoyang Wen
IPC分类号： C07D471/04 , A61K31/497 , A61K31/55 , A61K31/496 , A61K31/551 , A61K31/5377 , C07D471/10 , A61K31/506 , A61K31/438 , A61P35/00 , A61P37/00 , A61P9/00 , A61P31/12 , A61P29/00 , A61P3/00 , A61P5/00 , A61P25/00 , A61P35/02 , A61K31/573 , A61K31/675 , A61K31/704 , A61K31/4745 , A61K39/395 , A61K31/664 , A61K31/69 , A61K31/436 , A61K31/7068 , A61K31/437
CPC分类号： C07D471/04 , A61K31/437 , A61K31/496 , A61K31/497 , A61K31/4995 , A61K31/506 , A61K31/55 , A61K31/551 , A61K45/06 , C07D231/00 , C07D519/00
摘要： Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
摘要翻译：式I的吡唑并[3,4-c]吡啶化合物，包括立体异构体，几何异构体，互变异构体及其药学上可接受的盐，其中R 1和R 2如本文所定义，可用于抑制Pim激酶，由Pim激酶介导的癌症。公开了使用式I化合物在体外，原位和体内诊断，预防或治疗哺乳动物细胞或相关病理状况中的这种病症的方法。

6. 发明申请

US20130006696A1 SYSTEM AND METHOD FOR AN EXTENSIBLE WORKFLOW MANAGEMENT 审中-公开
标题翻译：用于可扩展工作流管理的系统和方法
公开(公告)号：US20130006696A1
公开(公告)日：2013-01-03
申请号：US13615181
申请日：2012-09-13
申请人： Kenny Wai-doon LOUIE , Chung Foo WU , Patrick-Alain Joseph NUMAINVILLE , Vernon-Joseph CHIN , Pui Wing Arthur LO , Shuk Yee Wendy LEE , Thomas LIGOCKI
发明人： Kenny Wai-doon LOUIE , Chung Foo WU , Patrick-Alain Joseph NUMAINVILLE , Vernon-Joseph CHIN , Pui Wing Arthur LO , Shuk Yee Wendy LEE , Thomas LIGOCKI
IPC分类号： G06Q10/06
CPC分类号： G06F3/04847 , G06F3/0484 , G06Q10/06 , G06Q10/06316
摘要： A workflow management system provides a GUI Configurability tool that allows an end user to configure the system's workflow screens, workflow logic and data fields without the need to rewrite any programs. The system allows each workflow screen to represent and assist each individual task within a business process that may be defined and illustrated by a flowchart. The workflow screens work in conjunction with workflow logic to create an accurate one-to-one mapping of the individual tasks and decision logic within a business process flowchart. The system provides published interfaces that allow the use of third party hardware and software within workflows. The system also provides published interfaces to integrate extensible code that perform custom functions within the system.
摘要翻译：工作流管理系统提供GUI配置工具，允许最终用户配置系统的工作流程屏幕，工作流逻辑和数据字段，而无需重写任何程序。该系统允许每个工作流屏幕表示和协助业务流程中的每个单独任务，该业务流程可由流程图定义和说明。工作流屏幕与工作流逻辑一起工作，以在业务流程图中创建单个任务和决策逻辑的准确的一对一映射。该系统提供已发布的界面，允许在工作流程中使用第三方硬件和软件。该系统还提供已发布的界面，以集成在系统中执行自定义功能的可扩展代码。

7. 发明授权

US08288381B2 N-9 substituted purine compounds, compositions and methods of use 有权
标题翻译： N-9替代嘌呤化合物，组合物和使用方法
公开(公告)号：US08288381B2
公开(公告)日：2012-10-16
申请号：US12943284
申请日：2010-11-10
申请人： Zhonghua Pei , Joseph P. Lyssikatos , Kevin Hon Luen Lau , Wendy Lee , Kirk D. Robarge
发明人： Zhonghua Pei , Joseph P. Lyssikatos , Kevin Hon Luen Lau , Wendy Lee , Kirk D. Robarge
IPC分类号： A61K31/52 , A61P35/00 , C07D473/34 , C07D473/40
CPC分类号： A61K31/52 , A61K31/5377 , C07D473/34
摘要： The present invention relates to compounds of Formula I: wherein R1, R2, R3, A1, A2, A3, A4 and D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.
摘要翻译：本发明涉及式I化合物：其中R1，R2，R3，A1，A2，A3，A4和D具有本文所述的含义。本发明还涉及包含这些化合物的药物组合物及其治疗用途。

8. 发明申请

US20120178780A1 RAF KINASE INHIBITORS 审中-公开
标题翻译： RAF激酶抑制剂
公开(公告)号：US20120178780A1
公开(公告)日：2012-07-12
申请号：US13424111
申请日：2012-03-19
申请人： Jill E. WOOD , Hanno Wild , Daniel H. Rogers , John Lyons , Michael Katz , Yolanda Caringal , Robert Dally , Wendy Lee , Roger A. Smith , Cheri Blum
发明人： Jill E. WOOD , Hanno Wild , Daniel H. Rogers , John Lyons , Michael Katz , Yolanda Caringal , Robert Dally , Wendy Lee , Roger A. Smith , Cheri Blum
IPC分类号： A61K31/381 , A61K31/4155 , A61K31/437 , A61K31/34 , A61K31/40 , A61K31/404 , A61K31/427 , A61K31/4025 , C07D333/38 , C07D417/12 , C07D409/12 , C07D307/68 , C07D207/34 , C07D471/04 , A61P35/00 , A61K31/433
CPC分类号： C07D207/34 , C07D307/68 , C07D333/38 , C07D409/12 , C07D417/12 , C07D471/04
摘要： Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.
摘要翻译：治疗由raf激酶介导的肿瘤与取代的脲化合物及其化合物本身的方法。

9. 发明申请

US20100331305A1 OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE 审中-公开
标题翻译：氧化杂环化合物吡嗪化合物，组合物和使用方法
公开(公告)号：US20100331305A1
公开(公告)日：2010-12-30
申请号：US12821998
申请日：2010-06-23
申请人： Philippe Bergeron , Frederick Cohen , Anthony Estrada , Michael F.T. Koehler , Cuong Ly , Joseph P. Lyssikatos , Zhonghua Pei , Wendy Lee , Xianrui Zhao
发明人： Philippe Bergeron , Frederick Cohen , Anthony Estrada , Michael F.T. Koehler , Cuong Ly , Joseph P. Lyssikatos , Zhonghua Pei , Wendy Lee , Xianrui Zhao
IPC分类号： A61K31/5377 , C07D491/052 , A61P35/00 , A61P35/04 , A61K31/519 , C07D491/10 , C07D498/08 , A61K31/5386
CPC分类号： C07D491/052 , C07D491/048 , C07D491/18 , C07D519/00
摘要： Disclosed are compounds of Formula I, including steroisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, that are useful in modulating PIKK related kinase signaling, e.g., mTOR, and for the treatment of diseases (e.g., cancer) that are mediated at least in part by the dysregulation of the PIKK signaling pathway (e.g., mTOR).
摘要翻译：公开了式I化合物，包括立体异构体，几何异构体，互变异构体，溶剂合物，代谢物和药学上可接受的盐，其可用于调节PIKK相关激酶信号传导，例如mTOR，以及用于治疗疾病（例如癌症），至少部分地由PIKK信号通路的失调（例如mTOR）介导。

10. 发明授权

US07585888B2 Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders 失效
标题翻译：苯并呋喃和苯并噻吩衍生物可用于治疗高增殖性疾病
公开(公告)号：US07585888B2
公开(公告)日：2009-09-08
申请号：US12059984
申请日：2008-03-31
申请人： Chengzhi Zhang , Michael J. Burke , Zhi Chen , Jacques P. Dumas , Dongping Fan , Jianmei Fan , Holia Hatoum-Mokdad , Benjamin D. Jones , Gaetan Ladouceur , Wendy Lee , Barton Phillips
发明人： Chengzhi Zhang , Michael J. Burke , Zhi Chen , Jacques P. Dumas , Dongping Fan , Jianmei Fan , Holia Hatoum-Mokdad , Benjamin D. Jones , Gaetan Ladouceur , Wendy Lee , Barton Phillips
IPC分类号： A61K31/343 , A61K31/381
CPC分类号： C07D307/82 , C07D307/92 , C07D307/93 , C07D333/66 , C07D333/74 , C07D333/78 , C07D405/04 , C07D405/06 , C07D405/10 , C07D405/14 , C07D407/06 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/06 , C07D417/04 , C07D417/06 , C07D493/04
摘要： This invention relates to novel benzofuran and benzothiophene derivatives of the general formula and their use for the treatment of hyper-proliferative disorders.
摘要翻译：本发明涉及通式的新型苯并呋喃和苯并噻吩衍生物及其用于治疗高增殖性疾病的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式